Manufacturers that dominate the U.S. market for puberty blockers refuse to conduct safety trials on their frequently prescribed off-label use to treat gender dysphoria in adolescents. Endo International plc and AbbVie Inc have repeatedly declined to conduct safety tests on the puberty blocking drug Lupron, according to a <a href="https://www.reuters.com/investigates/special-report/usa-transyouth-care/?scrolltoken=w-0Z84Gp-uYQHFImjLpWNA3r5HIT9-yIuyBSZTBPNeU50SsEIYjJF4u_ibxizWMwBQ4pTfaxz38rn_qaKqouFSxB7nMhksmEzh-G7wckT8RSEQrssc98m9uhQmkZUB9foiji5AHDtrQMfgxMh-I7U4AOLtEDmoG6xga4eUzqpivL4ThQaxKyypE6Sr5jMnVxSNz_1FI-rI3YcCnenrwHs9AFCZVDkNOW1XcWkxXr9g.eyJraWQiOiIzIn0" target="_blank" rel="noopener">new report</a> by Reuters.
Left-wing news outlet Reuters published <a href="https://www.reuters.com/investigates/special-report/usa-transyouth-data/?scrolltoken=whs3RN_MoirIfvILiMHhJ7GbGiI55wzId7NgSE-9mKZWJzXo6aHu_SgreiLwiSP-Ta1397LOJpYmQ3CYNDe8PohA0ZWUc7sbpC3Ql-Yhnoxo3ZVvi1FxdWplE-LvO7sME8hKRUfRkOxkVwyFulf5EOI1nGZTtMrZUbkJh2jkIdoduUFCPeZTphGKMV07AcwLjB1hsKZQtXBOTjt6WG6OJ2q7DB1Q7H0rL1mecL9jIg.eyJraWQiOiIzIn0" target="_blank" rel="noopener">data</a> on Thursday about the rising number of children and adolescents adopting a transgender identity and seeking medical interventions. Among the shocking revelations is that between 2017 to 2021, 17,683 of the 121,882 children ages 6 to 17 diagnosed with gender dysphoria received puberty blockers or cross-sex hormones. Despite such widespread adoption for the drug’s off-label use, the drug’s manufacturers refuse to conduct safety trials for their use in treating gender dysphoria in adolescents.
Dr. Brad Miller, division director of pediatric endocrinology at the University of Minnesota Medical School and M Health Masonic Children’s Hospital, and “several other doctors,” told Reuters they had “repeatedly asked” AbbVie, Endo, and other manufacturers of puberty blockers to seek FDA approval for the drugs in treating gender dysphoria in children and to conduct clinical trials to establish their safety. “They said the companies always declined,” reported Reuters.
“They would say it would cost a lot of money to get approval,” Miller said of the drug manufacturers’ refusal. “And they were not interested in going there because (transgender treatment) was a political hot potato.”
Miller told Reuters he was “particularly concerned” because doctors prescribe puberty blockers for trans-identifying children, who are “already at higher risk of mental health problems.”
Reuters attempted to reach AbbVie, but they declined to give comment. “An Endo spokeswoman said the company has no plans to seek regulatory approval for the use of its drug for any new indications,” said Reuters, adding, “The company did not respond to requests for further comment for this article.”
Puberty blocking drugs are only FDA-approved for their use in treating central precocious puberty, a condition caused by pituitary gland dysfunction in which children begin to sexually mature before age 8 or 9. They are not approved for their off-label use in treating gender dysphoria in adolescents, which is during a critical window of brain and body development. Many of the existing published data pertain only to precocious puberty patients.
Reuters reported on the side effects of puberty blocking drugs prescribed to children, which include a decline in bone density, neurological effects, and psychiatric problems.
Reuters reported they have found 72 adverse event reports submitted to the FDA from 2013 through 2021 of children on puberty blockers who showed “suicidal, self-injurious, or depressive behavior.” This data includes taking the drug for either central precocious puberty or gender dysphoria, some of which were identified simply as “under 18,” Reuters noted.
In 2016, the FDA ordered puberty blocking drugmakers to add a warning about psychiatric problems to the drugs’ labels as a treatment for children with precocious puberty. On its label for Lupron, the brand name of the puberty blocking drug leuprolide, AbbVie says: “Psychiatric events have been reported in patients” taking puberty blockers. Events include emotional symptoms “such as crying, irritability, impatience, anger and aggression.”
On the potential neurological effects of puberty blockers, some scientists and doctors have voiced concerns, Reuters said. “Hormones released during puberty play a major role in brain development, so when puberty is suppressed, can that result in reduced cognitive function, such as problem solving and decision making?” Reuters asked.
A 2020 paper by Dr. John Strang, research director of the gender development program at Children’s National Hospital, and other researchers wrote that “pubertal suppression may prevent key aspects of development during a sensitive period of brain organization.”
Reuters quoted Strang as saying, “we need high-quality research to understand the impacts of this treatment – impacts which may be positive in some ways and potentially negative in others.”

<script async src="https://www.instagram.com/embed.js"></script>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
<script async src="https://www.tiktok.com/embed.js"></script><div data-widget-host="revcontent" data-pub-id="165152" data-widget-id="290588"></div><script src="https://delivery.revcontent.com/165152/290588/widget.js"></script>

Puberty Blocking Drug Companies Refuse To Conduct Safety Trials

CONTINUE READING

‘Harry Potter’ Starlet Evanna Lynch Shows Support For Detransitioners

Lawsuit Alleges New York Trans Teacher ‘Forced’ 5th-Grader To Change Name, Pronouns

‘Detransition Awareness Day’ Event Poised To Yield Largest Turnout Yet

Detransitioner Takes First Legal Action In Spain Against Health Provider That Transitioned Her As A Minor

Kansas Senate Passes First Bill Defining ‘Woman’ As A Biological Female

Transsexuals Pen Letter Asking U.S.-Based Medical Organizations To Reject Ideology In Favor Of Evidence

News

Original

Children

Drugs

LGBTQ

Puberty blockers

Transgender

A video goes viral showing a baby being refused his mother by two gay "dads". This is just the tip of the iceberg, which is why we will have an important discussion today about surrogacy. 

Hour 1

The Matt Walsh Show

Ep. 1765 - This Video Is One Of The Worst Things I've Seen In A Long Time 

The Strait of Hormuz officially opens for business (kind of), the Pope makes “shocking” comments on immigration, and President Trump promises UFO disclosure at TPUSA. 


The Michael Knowles Show

Ep. 1956 -  Pope Leo's "SHOCKING" Immigration Comments EXPLAINED

A false miscreed has corrupted our leadership class.


The Andrew Klavan Show

Ep. 1275 - Dumb, Dumber and Progressive

President Trump announces a 10-day ceasefire between Lebanon and Israel, a murder-suicide involving former Democratic Lieutenant Governor Justin Fairfax shakes Virginia, and France and Britain hold a conference to secure the Strait of Hormuz – after the Iranian conflict ends. Get the facts first with Morning Wire.

- - -

Ep. 2738

- - -

Wake up with new Morning Wire merch: https://bit.ly/4lIubt3

- - -

Today's Sponsors:

Alliance Defending Freedom - Visit https://JoinADF.com/WIRE or text 'WIRE' to 83848 to learn more.

Pocket Hose - Text MORNING to 64000 to get a FREE pocket pivot and their 10-pattern sprayer with the purchase of ANY size Copper Head hose. Message and data rates may apply.

Morning Wire

U.S. Expands Hormuz Blockade & VA Fairfax Deaths Investigated | 4.17.26

U.S. Expands Hormuz Blockade & VA Fairfax Deaths Investigated | 4.17.26 [Member Exclusive]

A ceasefire goes into effect between Israel and Lebanon, a tragic murder-suicide rocks Virginia, and Dairy Queen deploys AI in the drive-thru. Get the facts first with Evening Wire.
- - -
Ep. 2737
- - -
Wake up with new Morning Wire merch: https://bit.ly/4lIubt3 
- - -
Today’s Sponsor:

Alliance Defending Freedom - Visit https://JoinADF.com/WIRE or text “WIRE” to 83848 to learn more.


Evening Wire: Lebanon Ceasefire Begins & Murder-Suicide Rocks VA | 4.16.26

The Pendragon Cycle

Menu

— News —

Puberty Blocking Drug Companies Refuse To Conduct Safety Trials